SCHEMBL31678841

SCHEMBL31678841

CCc1c(-c2ccccc2N)c(=O)n2c(-c3ccccc3)c(C)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.39
▸ TP53 P04637 2/20 0.39
▸ LMNA P02545 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ AKR1B1 P15121 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ KDR P35968 2/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ TNF P01375 1/20 0.36
▸ NOD1 Q9Y239 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31678803 0.91 MAPT (0.39) MAPTTP53AKR1B1KDM4EKMT2A
SCHEMBL31678252 0.89 KDM4E (0.40) MAPTTP53AKR1B1KDM4EKMT2A
SCHEMBL31678842 0.88 KDR (0.37) MAPTTP53LMNAHTTAKR1B1
SCHEMBL31677815 0.87 KDM4E (0.40) MAPTTP53AKR1B1KDM4EKMT2A
SCHEMBL31678836 0.87 MAPT (0.39) MAPTTP53LMNAHTTAKR1B1
SCHEMBL31678790 0.86 AKR1B1 (0.40) MAPTTP53LMNAHTTAKR1B1
SCHEMBL31677705 0.85 KMT2A (0.41) MAPTTP53LMNAKDM4EKMT2A
SCHEMBL31664583 0.83 MAPT (0.41) MAPTTP53LMNAAKR1B1KDM4E
SCHEMBL31678727 0.80 AKR1B1 (0.41) MAPTTP53AKR1B1KDM4EKMT2A
SCHEMBL31677806 0.79 AKR1B1 (0.40) MAPTTP53LMNAAKR1B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS WRN, RECQL, BLM MAPT 4574/4885TP53 68/4885LMNA 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback